Martin King MD, PhD

Martin King, MD, PhD, is a board-certified radiation oncologist who specializes in treating gynecologic and genitourinary cancers with both external and internal radiation therapy (e.g. brachytherapy). Dr. King completed radiation oncology residency at Stanford Hospital and Clinics, followed by a brachytherapy fellowship at the Memorial Sloan-Kettering Cancer Center. Since then, he initiated the high-dose-rate prostate brachytherapy program at the Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center. Dr. King currently performs over 100 prostate implants per year for patients with localized, locally advanced, and radiorecurrent disease. He also leads the Brachytherapy Clinical Operations Leadership Team at his institution.

Dr. King's current area of excellence is clinical expertise and innovation. His specific goal is to identify therapeutic strategies that can improve quality of life and access to care for patients with pelvic malignancies. With respect to quality of life, he is the lead principal investigator of two multi-center randomized controlled trials focused on improving quality of life for patients with prostate cancer undergoing radiation therapy. The INTREPId randomized trial evaluates whether a novel second-generation anti-androgen darolutamide can be utilized in place of traditional androgen deprivation therapy for preserving erectile function while not sacrificing the potential for long-term disease control. Another randomized trial evaluates whether a novel rectal hydrogel spacer can improve both bowel and sexual function in men receiving hypofractionated radiotherapy.

Dr. King has also published multiple articles evaluating the oncologic implications of therapeutic de-escalation for locally advanced prostate cancer. Furthermore, he has drafted guidelines for the utilization of low dose rate prostate brachytherapy that have been approved the boards of the American Brachytherapy Society and the American Society for Radiation Oncology.